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Abstract 
Choo YC (Division of Gynecologic Oncology, 
Department of Obstetrics and Gynecology, 
University of Michigan Medical School, Ann 
Arbor, MI, U.S.A.). Chemotherapy in 
advanced primary and recurrent cervical carci- 
noma. 
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Chemotherapy in carcinoma of the cervix 
continues to be a therapeutic challenge. The 
diversified treatment programs from one 
institution and the factors affecting response 
are analyzed. It is concluded that until more 
active regimens are available, chemotherapy 
in advanced and recurrent cervical carcinoma 
should be confined to patients with good 
prognostic factors. 
Key words: Cervical neoplasm; Drug therapy 
Introduction 
The incidence of invasive carcinoma of the 
cervix has declined considerably within the 
past decade due largely to the detection and 
treatment of the pre-invasive disease, but 
stage for stage, no improvement in the 
survival of the invasive disease has been 
recorded. While surgery and radiation are 
equally efficacious for the early stages and 
radiation only is employed for the later 
stages, chemotherapy plays a role in meta- 
static primary disease and advanced recurrent 
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disease. Adjunctive chemotherapy has been 
suggested in patients in whom paraaortic 
nodal metastasis have occurred when the 
disease is considered systemic, but its value 
is unknown. The response and success of 
chemotherapeutic agents in carcinoma of the 
cervix have been disappointing; the overall 
response rate is generally around 20-30%, 
usually lasting for a few months only, and 
complete remission is rare [ 11. In recent 
years, one witnesses the evolution of single 
to multiple agents in the chemotherapy of 
carcinoma of the cervix. Drugs that have 
been reported to be active are as shown 
in Tables I and II. At the University of 
Michigan Hospital, diversified regimens of 
chemotherapy have been employed in 
keeping with this trend; these also provided 
valuable experience in the use of various 
drugs. This study serves to analyze our 
results in the application of these agents 
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Table II. Combination agents active in carcinoma of the 
cervix. 
Bleomycin/mitomycin C [2] 
Vincrlstine/bleomycinin/mitomychi C [ 3) 
Adriamycin/methotrexate [4] 






and to categorize prognostic factors, if any, 
related to patient selection and response in 
chemotherapy treatment of carcinoma of 
cervix. 
Materials and methods 
During the 6-year period from January 
1974 through December 1979, 523 cases 
of cervical carcinoma were seen at this 
institution. Nineteen patients had meta- 
stasis outside the pelvis when first seen 
(Stage IVB), or developed metastasis 
during or soon after radiotherapy. Eighty 
patients developed advanced recurrent 
carcinoma following initial surgery or 
radiation. Chemotherapy would have 
formed the basis of treatment in these 
99 patients but 19 patients either refused 
chemotherapy or had such a low Kanofsky 
index that chemotherapy would not deem 
to be beneficial. At this institution, the 
gynecologic oncologist is primarily 
responsible for chemotherapy of 
gynecologic cancers. Single agents that 
have been used in this institution in 
cancer of the cervix included cytoxan, 
Table III. Single agents used in carcinoma of the cervix at 
the University of Michigan Hospital. 
Cytoxan, 100 mg/m* p.o. or 1 g/m’ i.v. q 3 weeks. 
Methotrexate, 25 mg i.v. weekly. 
Adriamycin, 60 mg i.v. q 3-4 weeks. 
C&platinum, 60-100 mglm’ i.v. q 3 we&s. 
Bleomycin infusion, 20 mg/day X 5 days q 4 weeks. 
methotrexate, adriamycin, &platinum 
and bleomycin infusion (Table III). 
Combination agents used included 
adriamycin/cytoxan, bleomycin/vincristine/ 
mitomycin C/methotrexate (BOMM), BOMM 
induction followed by consolidation treat- 
ment with adriamycin/cis-platinum/cytoxan 
(BOMM-APC), vincristine/Hluorouracil 
infusion, vincristine/mitomycin C/bleomycin 
(Table IV). The BOMM and BOMM-APC 
regimens were adopted from protocols used 
by the Medical Oncology Department for 
head and neck cancers. Adriamycin/cytoxan 
regimen was the most common combination 
used, but lately BOMM-APC regimen was 
given more frequently. All patients underwent 
appropriate work-up studies which included 
an IVP, cystoscopy, sigmoidoscopy, chest 
X-ray, biochemical blood tests, and a liver 
and bone scan when indicated. Most of the 
patients also had a lymphangiogram, and 
selected patients also underwent fine needle 
aspiration of the abnormal nodes under 
fluoroscopy for cytology when their 
lymphangiograms were abnormal. The 
standard criteria for response were used. 
Complete response was defined as complete 
absence of detectable disease for 3 months 
-or more; partial response as 50% or more 
reduction in the product of the perpendicular 
measurable diameters for 3 months or more. 
Lesser degree of responsiveness was classified 
as stable disease. Progression was defined as 
increase in size of the measurable lesion. In a 
few instances where the lesion was not 
clinically evident such as disease proven in 
the lymph nodes, the disease free interval 
was used as the criterion of response. 
Results 
Primary carcinoma - persistent or metastatic 
Table V lists the 19 patients with primary 
carcinoma of the cervix and the indications 
for chemotherapy. Twelve patients had 
Stage IVB disease while the rest had meta- 
stasis during or soon after radiation, or had 
persistent disease not amenable to surgery. 
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Adriamycin, 60 mg/m’ i.v. q 3 weeks 
Cytoxan, 600 mgjm’ i.v. q 3 weeks 
Bleomycin/vincristine/mitomycln C/methotrexate (BOMM) 
Vincristine, 1.5 mg/m* i.v., repeat in 4 weeks 
Mitomycin, C, 15 mg/m’ 6 h after vincristine at Initial course only 
Bleomycin, 20 U/24 h infusion X 4 days. Repeat in 4 weeks. 
Methotrexate, 30 mg/m’ i.v. 3fj h after bleomycin infusion, then q 1 week 
Vincristine/bleomycin/mitomycin C. 
As in BOMM but without methotrexate 
Bleomycin/vincristine/mitomycin C/methotrexate-Adriamycin/CYs-platinum/cytoxan (BOMM-APC) 
Vincristine, 2.0 mg i.v. q 4 weeks X 2,6 h prior to mitomycin C and bleomycin infusion 
Mitomycin C, 15 mg/m’ i.v. at beginning of first bleomycin infusion only 
Bleomycin, 20 units/24 h X 4 days q 4 weeks X 2 
Methotrexate, 30 mg/m* i.v. 36 h after bleomycin, then twice weekly 
Leukovorin factor, 20 mg 24 h after methotrexate 
Cis-platinum, 60 mg/m* infusion 4 weeks after BOMM and q 3 weeks 
Adriamycin, 40 mg/m’ i.v. 4 weeks after BOMM and q 3 weeks 
Cytoxan, 400 mg/m’ iv. 4 weeks after BOMM and q 3 weeks 
Vmcristine/S-fluorouracil 
Vincristine, 1.5 mg/mz iv. days 1 and 2 q 4 weeks 
5-Fluorouracil, 600 mg/m’/24 h X 5 days q 4 weeks 
The sites of disease or metastasis are as 
shown in Table VI. In their initial work up, 
six had unilateral ureteral obstruction; 10 had 
an abnormal lymphangiogram for which five 
lymph node aspirations were performed, 
yielding three positive cytology. Radiation 
treatment was instituted in 15 patients - 
seven had palliative cesium. The remaining 
four patients had metastasis outside the pelvis 
but minimal local symptoms and they 
received chemotherapy only. Of the 15 
patients who were given radiation, 12 also 
received adjunctive chemotherapy while three 
either refused or were unfit for chemotherapy. 
The first line chemotherapy and the 
response are shown in Table VII. Complete 
response was noted in three patients (18.8%), 
partial response in one (6.3%), and stable 
disease in two (12.5%). Three out of eight 
patients who received adriamycin/cytoxan 
regimen responded (37.5%): one patient who 
had unilateral ureter-al obstruction and lymph 
node metastasis in the neck treated by radical 
radiation and chemotherapy is alive with no 
disease for 5 years; one patient had partial 
response for 7 months but succumbed to 
progressive disease 3 months later; another 
patient who had multiple metastasis to the 
lungs but minimal cervical disease had partial 
response and is alive after 20 months of treat- 
ment with adriamycin/cytoxan regimen only. 
Cytoxan resulted in complete remission in 
Table V. Chemotherapy in advanced primary carcinoma of the cervix - stages and indications. 
Stage No. Indication 
IB 1 Metastasis to lungs while on radiation 
II 1 Lymph node metastasis to the neck on completion of radiation 
III 2 Persistent disease following radiation 
IVA 2 1, persistent digease following radiation and the other, metastasis to the spine while on radiation 
IVB 12 Metastasis outside the pelvis 
Unstaged 1 Inadvertent hysterectomy followed by radiation. Persistent disease 
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Table VI. Sites of metastasis in patients with primary 
carcinoma of the cervix. 
Lung 7 
Neck nodes 6 
Pelvic and/or paraaortic no&s 4 
Spine 1 
Spine and lungs 1 
TOTAL 19 
a patient who had adenocarcinoma of the 
cervix with metastasis to the lungs for 
20 months but she died of a carcinoma of 
the breast. Two patients on BOMM-APC 
are presently alive: one has stable disease 
for 6 months and the other has complete 
response for 9 months. When these patients 
are analyzed, it is observed that two patients 
were given radical radiation, two had 
palliative cesium, and in the other two, no 
radiation at all was given. The sites of 
metastasis were the supraclavicular nodes in 
five and the lungs in one. Also noted was the 
absence of clinical local disease following 
treatment. 
Second line chemotherapy was instituted 
in five patients but none showed any 
response. 
Among those patients who did not respond 
to chemotherapy, the average survival was 
5.9 months. The three patients who received 
no chemotherapy but only palliative cesium 
treatment died of their disease after an 
average interval of 6 months. 
Complications of chemotherapy were 
noted in only four patients: three had mild 
to moderate leukopenia, one had severe 
leukopenia and sepsis from BOMM-APC and 
required antibiotics, one patient had reduced 
EKG voltages necessitating discontinuation 
of adriamycin. 
Recuwen t carcinoma 
Among the 80 patients who had recurrent 
cervical carcinoma, three had initial radical 
hysterectomy, 69 were treated by radiation 
for their primary disease and eight had radical 
hysterectomy or inadvertent simple hyster- 
ectomy followed by radiation. Their original 
disease was Stage I in 17, Stage II in 38, 
Stage III in six, Stage IV in three, and un- 
staged or unknown in 16 patients. The sites of 
recurrence were pelvic, unamenable to 
exenteration in 47; distant metastasis with no 
pelvic recurrence in 22, and both distant 
metastasis and pelvic recurrence in 11 patients. 
Thirty-nine patients who had pelvic re- 
currence had lymphangiographic study per- 
formed, 32 were reported as abnormal. 
Lymph node aspiration was performed on 
11 patients, yielding seven positive cytology. 
Seventeen patients had positive direct lymph 
node biopsies, this was performed for 
exploration for possible exenteration or to 
ascertain a negative lymph node aspiration. 
During the initial period, patients who had 
ureteral obstruction as evidenced on IVP were 
invariably explored but all were discovered 
to have nodal spread of disease as well as 
Table VII. First line chemotherapy and response in patients with advanced primary carcinoma of the cervix. 
Regimen Response 
Stable Partial Complete Progression Total 
Adriamycin/cytoxan 2 1 5 8 
Cytoxan 1 3 4 
BOMM-APC 1 1 2 
Vincristine/S-fluorouracil 1 1 
Cis-platinum 1 1 
TOTAL 16 
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Table VIII. First line chemotherapy and response in patients with recurrent carcinoma of the cervix. 
Regimen Response 
Stable Partial Complete Progression Total 
Adriamycin/cytoxan I 19 26 
Adriamycin 2 13 15 
Cytoxan 2 I 9 
BOMM 2 3 5 
BOMM-APC 1 1 
C&platinum 2 ‘2 4 
Vincristine/5-fluorouracil 1 1 2 
Bleomycin 1 1 
Vincristie/mitomycin C/ 
bleomycin 1 1 
TOTAL 17 41 64 
disease spread to pelvic side wall. More 
recently, lymphangiograms were performed 
on these patients revealing a high rate of 
suspicious nodes. Such patients would then 
undergo fine needle aspiration of the 
suspicious nodes and with this technique we 
have obviated many unnecessary explorations. 
eight patients. One patient had severe 
leukopenia requiring prophylactic antibiotics. 
Two patients died from bleomycin pulmonary 
toxicity. 
Sixty-four patients received first line 
chemotherapy as shown in Table VIII. None 
had partial or complete remission. Fourteen 
patients had stable disease or disease free 
interval for an average duration of 7.7 months 
(21.9%), and for these patients, the average 
survival was 19.6 months. On the other hand, 
for those who failed to respond, the average 
survival was 7.6 months. For the remaining 
16 patients who received no chemotherapy, 
their average survival was 7.5 months. 
Analyzing the response to chemotherapy in 
relation to the location of the recurrent 
disease, it is noted that among 15 patients 
who had stable disease on first line chemo- 
therapy, 12 had distant recurrences without 
pelvic disease. Three response was observed in 
patients who had recurrence in the pelvis. All 
three patients who responded to second 
line chemotherapy again had disease in 
distant sites and not the pelvis. 
The stage of the initial disease and the 
interval between initial treatment and re- 
currence had no bearing on their response to 
chemotherapy. 
Fifteen patients received second line 
chemotherapy, one partial response was 
recorded with BOMM for 3 months, un- 
fortunately she succumbed to pulmonary 
toxicity. Two patients given cytoxan 
treatment had stable disease for an average 
duration of 9 months. 
Third line chemotherapy was instituted in 
seven patients, none had any response. 
Adriamycin/cytoxan was the most 
common regimen in fust line treatment, and 
stable disease was recorded in seven out of 
26 patients (26.9%). 
Ureteral obstruction was an ominous sign 
for prognosis in this group of patients. With 
unilateral obstruction, none lived for more 
than 8 months despite initial response from 
chemotherapy. With the presence of triad, 
i.e. unilateral ureteral obstruction, unilateral 
leg edema and leg pain, the survival dropped 
further to an average of 5.7 months. IIio- 
femoral venous obstruction also signified poor 
prognosis, and in two patients, their survival 
was less than 6 months, 
Discussion 
Mild to moderate leukopenia occurred in Despite many diversified chemotherapeutic 
In t J Gynaecol Obstet 20 
422 Choo 
agents being employed and new drug com- 
binations being reported, carcinoma of the 
cervix is still regarded a chemo-resistant 
cancer. The often mentioned difficulties 
encountered in chemotherapy in cervical 
cancer are: decreased chemo-perfusion when 
recurrence occurs in a previously irradiated 
pelvis; renal function impairment from 
ureteral obstruction precluding the use of 
active agents such as methotrexate and cis- 
platinum and affecting the pharmokinetics 
of many other agents; difficulty in evaluating 
responses because of prior fibrosis in the 
pelvis, and compromised bone marrow from 
prior irradiation of some one-third functional 
bone marrow affecting aggressive drug treat- 
ment. 
This study does not aim to compare the 
response and results of different chemo- 
therapy agents but serves to emphasize that 
chemotherapy can play a role in selected 
patients with primary metastatic and re- 
current carcinoma of the cervix. 
Since only a small percentage of patients 
with cervical cancer requiring chemotherapy 
will respond, it is vital to know who the 
potential candidates are and what kind of 
active agents are available. Also, the benefits 
of drug treatment should balance against 
potential complications and fatalities from 
such treatment. Cumulative reports have 
shown that active drugs presently employed 
in cancer of the cervix are confined mainly 
to adriamycin, cytoxan, methotrexate, 
cis-platinum, vincristine, bleomycin and 
mitomycin C. Although multiple combina- 
tion agents may show enhanced response, 
their effectiveness has not been proven to 
be superior to single agent alone; besides, 
the potential bone marrow depression 
warrants caution in their use. Drugs with 
irreversible potential complications such as 
bleomycin and &s-platinum should be used 
with extreme care with close monitoring. 
In our experience, adriamycin/cytoxan 
combination is an active regimen despite 
report to its contrary [ 1.11. Its accepta- 
bility and practicality also lie in its ease 
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of administration with bolus injections at 
3-4 weekly intervals without hospitaliza- 
tion, and its rarity of severe complications. 
The BOMM-APC regimen does show promise 
and further evaluation is underway. 
Favorable prognostic factors are distant 
metastasis to the lungs and lymph nodes; 
in particular patients with such metastasis 
without pelvic recurrence are favorable 
candidates for chemotherapy. The presence of 
ureteral obstruction alone, ilio-femoral vein 
thrombosis, and the triad of abnormal IVP, 
unilateral leg pain and edema are deterrans 
precluding favorable response to chemo- 
therapy. 
This study shows that partial and complete 
remissions are more frequent with primary 
metastatic carcinoma than recurrent carci- 
noma. The poorer result in the latter may be 
related to impaired vascular perfusion in the 
pelvis. But when patients with primary meta- 
static carcinoma fail to respond to chemo- 
therapy, their course is more rapid than those 
with recurrent disease. 
Regardless of the type of disease, however, 
for those who respond to chemotherapy, 
their survival can be meaningfully improved 
as opposed to those who do not respond. 
Those who fail to respond to first line chemo- 
therapy in all likelihood will probably not 
respond to further chemotherapy. 
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